Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy

Phase 2 Active not recruiting 15 enrolled Olivia Newton-John Cancer Research Institute Austin Health · collab Ballarat Health Services · collab Roche Products Pty Limited · collab

NaSingle-groupOpen-labelTreatment

Summary

This single-arm phase II interventional study aims to assess disease response to, and toxicity of, a combination of obinutuzumab and atezolizumab, with or without radiotherapy, in treatment naive Follicular Lymphoma. The study will involve an induction phase and a maintenance phase for responding participants, for up to 24 months. Response to treatment will be monitored using medical imaging and clinical assessment.

Timeline

Start: 2021-08-17
Primary completion: 2023-04-30
Completion: 2025-07

Outcome

Met primary endpoint

paper The primary end-point of complete response (CR) was achieved in 93% (95% confidence interval [CI]: 70%-99%) PMID 41949430 ↗

Publications

Martynchyk A, Chong G, Khor R, Lee D, Lee ST, Scott AM, Grobler AC, Campbell BA, Thachil T, Manos K, Douglas G, Romano A, Palmer JB, Burgess M, Keane C, Hawkes EA. Checkpoint inhibitors, obinutuzumab plus PET-adapted ultra-low dose nodal radiotherapy yield high efficacy in treatment-naive follicular lymphoma: Results from the phase II 'FLUORO' study. Br J Haematol. 2026 Jun;208(6):2026-2035. doi: 10.1111/bjh.70468. Epub 2026 Apr 8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Atezolizumab	Monoclonal antibody	1200 mg	Intravenous
Subject	Obinutuzumab	Monoclonal antibody	1000 mg	Intravenous